Animal health company Elanco (NYSE: ELAN) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 11.3% year on year to $1.27 billion. Guidance for next quarter’s revenue was better than expected at $1.20 billion at the midpoint, 1.3% above analysts’ estimates. Its non-GAAP profit of $0.27 per share was 32.8% above analysts’ consensus estimates.

Is now the time to buy ELAN? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Elanco’s third quarter results were well received by the market, reflecting momentum across its pet health and farm animal portfolios. Management credited strong demand for new pet health products—particularly Zenrelia and Credelio Quattro—as well as broad-based adoption in both U.S. and international markets, for driving revenue growth and margin expansion. CEO Jeff Simmons highlighted that, “efficacy is the clear driver” behind Zenrelia’s success, and emphasized that the company’s focus on differentiated innovation, supported by targeted investments in commercial infrastructure, resulted in share gains and improved profitability.

Looking ahead, Elanco’s updated guidance is underpinned by continued scaling of its innovation pipeline, expanded reach for recently launched products, and ongoing productivity initiatives. Management pointed to Befrena’s full-scale launch as a key growth driver in the coming year, with CFO Bob VanHimbergen stating that productivity measures—such as the Elanco Ascend program and increased use of automation—should support further margin improvement. The company anticipates its new product launches and omnichannel distribution capabilities will allow it to capture additional share, despite pockets of competitive pressure and industry shifts in pet owner purchasing behavior.

Key insights from management’s remarks

Management attributed the quarter’s results to robust innovation-driven growth, operational productivity improvements, and resilient customer demand across geographies and channels.

• Innovation portfolio momentum: Elanco’s Big 6 products, led by Zenrelia and Credelio Quattro, generated $328 million in quarterly revenue, with innovation sales up 40% year over year. Management emphasized strong demand in both the U.S. and internationally, noting Zenrelia’s growing market share in the U.S. JAK inhibitor segment and rapid adoption in Europe and Japan.

• Operational productivity gains: The company delivered a 300-basis-point gross margin expansion, citing favorable mix in pet health and ruminants, successful manufacturing improvements, and the impact of the Elanco Ascend productivity program. These efforts also contributed to accelerated debt paydown and improved free cash flow.

• Omnichannel and distribution expansion: Elanco highlighted progress in reaching pet owners through both veterinary clinics and retail channels, with AdTab experiencing more than 40% sales growth in the European over-the-counter segment. Despite a non-renewal with Costco, new retail partnerships are expected to offset any near-term impact.

• International pet health strength: Pet health revenue outside the U.S. grew 17% in constant currency, with Zenrelia nearing blockbuster status in international dermatology and AdTab becoming the fastest-growing brand in its European category.

• Farm animal segment resilience: The farm animal business posted growth, supported by strong cattle and ruminant portfolios. Management called out protein demand as a key driver but noted ongoing regional cycles, especially in dairy and swine, could introduce variability moving forward.

Drivers of future performance

Elanco expects new product launches, expanded distribution, and operational efficiencies to drive revenue and margin growth, even as it navigates evolving market dynamics and cost pressures.

• Befrena launch and innovation scaling: The full-scale U.S. launch of Befrena, alongside continued growth in Zenrelia and Credelio Quattro, is expected to be a major contributor to top-line growth next year. Management believes these products’ medical differentiation will sustain share gains despite increased competition.

• Productivity and margin initiatives: The Elanco Ascend program, which incorporates automation and procurement improvements, is projected to drive structural gross margin and EBITDA enhancements. Management expects ongoing benefits from procurement actions and manufacturing efficiencies as new contracts and automation gains flow through.

• Retail and distribution shifts: While the Costco contract non-renewal will affect first quarter retail sales, Elanco anticipates that additional retail partnerships and omnichannel strategies will more than offset this headwind over the full year. Management also highlighted resilience in pet health spending and shifting consumer preferences toward convenience as supportive trends.

Catalysts in upcoming quarters

In the quarters ahead, the StockStory team will track (1) the commercial rollout and adoption rate for Befrena and its impact on pet health growth, (2) execution of productivity and margin improvement initiatives under the Elanco Ascend program, and (3) continued success of new and existing products in capturing market share globally. Progress on new retail partnerships and resilience of farm animal demand will also be critical indicators.

Elanco currently trades at $25.70, up from $23.69 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

Stocks that trumped tariffs

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.